Skip to main content
Fig. 1 | Annals of Clinical Microbiology and Antimicrobials

Fig. 1

From: Antimicrobial activity of ceftazidime-avibactam and comparators against levofloxacin-resistant Escherichia coli collected from four geographic regions, 2012–2018

Fig. 1

Proportion of levofloxacin-resistant Escherichia coli isolates identified as ESBL-positive, 2012–2018. All regions: 2012, n = 487/1012; 2013, n = 792/1494; 2014, n = 844/1615; 2015, n = 718/1365; 2016, n = 901/1739; 2017, n = 887/1625; 2018, n = 1111/1990. Africa/Middle East: 2012, n = 39/86; 2013, n = 98/170; 2014, n = 109/204; 2015, n = 68/118; 2016, n = 77/157; 2017, n = 82/160; 2018, n = 136/246. Asia/South Pacific: 2012, n = 123/254; 2013, n = 148/291; 2014, n = 159/309; 2015, n = 152/271; 2016, n = 206/379; 2017, n = 204/358; 2018, n = 291/475. Europe: 2012, n = 175/422; 2013, n = 361/701; 2014, n = 347/727; 2015, n = 305/620; 2016, n = 316/709; 2017, n = 343/669; 2018, n = 443/815. Latin America: 2012, n = 150/250; 2013, 185/332; 2014, n = 229/375; 2015, n = 193/356; 2016, n = 311/494; 2017, n = 258/438; 2018, n = 241/454

Back to article page

Annals of Clinical Microbiology and Antimicrobials

ISSN: 1476-0711

Contact us